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Background. Obstructive Sleep Apnea Syndrome (OSAS) is associated with several morbidities. The most important ones 
are obesity, hypertension and diabetes mellitus. A clear relationship of OSAS and dyslipidemia is yet to be demonstrated. 
Objectives. To evaluate the prevalence of dyslipidemia as a morbidity associated with OSAS and to understand its relationship with 
the severity of OSAS.
Material and methods. We randomly selected 92 patients diagnosed until the end of May 2016 with OSAS from two primary health 
care units and 184 patients as controls (no OSAS diagnosed) from random lists of patients matched in age and gender with patients 
with OSAS. 
We calculated the prevalence of the classified comorbidities (overweight, hypertension, type 2 diabetes mellitus and dyslipidemia) in 
both groups. We used logistic regression to check the association between them. We evaluated the relationship between dyslipidemia 
and OSAS severity by using the Apnea/Hypopnea Index (AHI).
Results. The prevalence of dyslipidemia was 80% in patients with OSAS. Patients with OSAS were diagnosed as overweight (97%), 
had arterial hypertension (89%) and type 2 diabetes mellitus (43%). OSAS was not independently related to type 2 diabetes mel-
litus (p = 0.101) and to dyslipidemia (p = 0.389). However, overweight and arterial hypertension were related independently to OSAS 
(p < 0.001) with a risk for OSAS. The prevalence of dyslipidemia in patients with mild, moderate and severe OSAS was 22%, 13% and 
25%, respectively.
Conclusions. Patients with OSAS have a high prevalence of dyslipidemia despite not being independently related. There were no sta-
tistical differences between patients with mild, moderate and severe OSAS.
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Background
Obstructive Sleep Apnea Syndrome (OSAS) is the most com-
mon sleep disorder [1], and it is a significant source of morbidity 
and mortality [1–5]. It can be defined by transitory episodes of 
apnea, and it is characterized by the presence of sleep fragmen-
tation and excessive daytime sleepiness associated with cardio-
vascular and neurocognitive disorders [6]. This syndrome re-
lates to a state of chronic hypoxia caused by recurrent episodes 
of temporary total or partial obstruction of the upper airways 
during sleep [2, 6]. OSAS affects around 4% of middle-aged men 
and 2% of middle-aged women in developed countries [2, 6]. In 
Portugal, the prevalence of OSAS is estimated, in the population 
of 25 years of age or more, to be around 0.89% [5]. It generally 
affects middle-aged, obese male individuals [5]. Several studies 
recognize OSAS as an independent risk factor for cardiovascular 
diseases [2, 6, 7].
Dyslipidemia is one of the risk factors for atherosclerosis [8]. 
It is defined by an elevation of total cholesterol (≥ 190 mg/dl), 
a reduction of HDL (≤ 40 mg/dl in men and ≤ 45 in women), an 
elevation of LDL (≥ 115 mg/dl) and triglycerides (≥ 150 mg/dl) 
[8]. The Portuguese prevalence of hypercholesterolemia is 47%, 
and an elevation of LDL occurs in 38% [9]. Hypertriglyceridemia 
is less prevalent, affecting about 13% of the population [9].
Several comorbidities have been associated with OSAS, 
among them, cardiovascular complications [10]. In Portugal, the 
most frequent cardiovascular risk factors in patients with OSAS 
are arterial hypertension (75.9%), obesity (74.2%) and diabetes 
mellitus (34.1%) [5].
Dyslipidemia has been studied as a comorbidity related to 
OSAS, but studies of such association are scarce, and clinical evi-
dence is limited [7, 11, 12]. Some studies have shown evidence 
of an existing relationship between the elevation of the preva-
lence of dyslipidemia and OSAS, but a clear association has not 
yet been found [2, 4, 10–15]. Dyslipidemia and OSAS severity 
could be related, higher levels of dyslipidemia being associated 
with increased Apnea/Hypopnea Index (AHI) [2]. As such, re-
inforcing cardiovascular prevention of dyslipidemia and acting 
therapeutically could be important in improving cardio-vascular 
health associated with OSAS [5].




























The aim of this study was to evaluate the prevalence of dyslip-
idemia as a comorbidity associated with OSAS and to understand 
its relationship with the severity of OSAS and its complications.
Material and methods
This was an observational cross-sectional study involving 
a target population of patients with Obstructive Sleep Apnea 
Syndrome (OSAS) followed in a General Practice and Family 
Medicine setting from two Primary Care Units in Central Por-
tugal in 2016. 
As exclusion criteria: patients with the P06 International 
Classification for Primary Care2 (ICPC2) code who were not 
treated using continuous positive airway pressure (CPAP) and 
patients with other types of sleep disturbance (insomnia, hy-
persomnia, nightmares and sleepwalking). Data was gathered 
from randomly selected e.processes from the patient lists of 
both health units using the mim@uf program until obtaining 
the needed sample. In the second stage, the same data was col-
lected for controls (without OSAS) using random lists paired in 
age and gender with the cases of OSAS.




• Body Mass Index (BMI) in kg/m2 registered in the pro-
cess,
• dyslipidemia/lipids metabolism coded on the list of 
problems (T93),
• Arterial Hypertension (HTA) coded in the list of prob-
lems (K86),
• type 2 Diabetes Mellitus (DM) coded in the list of prob-
lems (T90),
• total cholesterol, LDL, HDL and triglycerides values,
• Apnea/Hypopnea Index (AHI) registered in the process 
(only for the cases),
• anti-dyslipidemia drugs prescribed during the last 6 
months,
• questionnaire with the variables under study: 
 - Mild OSA: IAH = 5.0–15.0/h,
 - Moderate OSA: IAH = 15.1–30.0/h,
 - Severe OSA: IAH > 30.0/h.
Data was collected from October to December 2016 after its 
approval by the Ethics Commission of ARS Center and authoriza-
tions from the Health Units.
Qualitative measures were described using absolute and 
relative frequencies, and the quantitative measures were de-
scribed by their average and standard deviation when normally 
distributed.
Student's t-test was used for independent numeric variables 
in the groups with and without OSAS. A bivariate analysis was 
performed between OSAS and each of the associated comorbid-
ities (overweight, arterial hypertension and diabetes mellitus) 
and between dyslipidemia and AHI.
A multivariate analysis by logistic regression was performed 
to evaluate the independent relationship between each of the co-
morbidities and OSAS, determining the respective relative risks. 
Any value of p < 0.05 was considered statistically significant.
Results
The sample of 92 OSAS cases and 184 controls used in this 
study was mostly made up of male individuals (74%) aged be-
tween 35 and 89. The average age was 63.763.7 ± 10.3 years 
(Table 1). No significant statistical differences were found be-
tween the group of patients with OSAS and the group without 
OSAS for gender and age. 
Table 1. Sample demographic characterization
Parameters Cases (n = 92) Controls (n = 184) p
Gender (M:F) 68 (74%):24 (26%) 136 (74%):48 (26%) 1
Average age 63.7 ± 10.3 63.7 ± 10.3 1
Minimum age 35 35 1
Maximum age 89 89 1
The data is presented by absolute frequency and proportion or aver-
age and standard deviation. Chi-squared and Student's t-test tests were 
used for independent samples. 
The data is presented by absolute frequency and proportion 
or average and standard deviation. Chi-squared and Student's 
t-tests were used for independent samples.
In a bivariate analysis, significant statistical differences were 
observed in all comorbidities between the group of patients 
with OSAS and without OSAS. The most frequent comorbidities 
in patients with OSAS were overweight (97%), arterial hyperten-
sion (89%) and dyslipidemia (80%). Type 2 diabetes mellitus was 
found in 43% of the patients (Table 2).
Table 2. Association of comorbidities of patients from the study 
with OSAS
Parameters OSAS (n = 92) Controls (n = 184) p
Overweight 89 (97%) 148 (81%) < 0.001
Arterial hyper-
tension
82 (89%) 125 (68%) < 0.001
Dyslipidemia 74 (80%) 110 (60%) < 0.001
Type 2 diabetes 
mellitus
39 (43%) 42 (23%) < 0.001
The data is presented by absolute frequency and proportion. The chi-
squared test was used.
A multivariate analysis to study the relationship of OSAS 
with each of the associated comorbidities (overweight, HTA, 
type 2 diabetes mellitus and dyslipidemia) was carried out. 
OSAS was not independently related to diabetes mellitus type 
2 (p = 0.101) and to dyslipidemia (p = 0.389). However, over-
weight and arterial hypertension were independently related 
with OSAS, with a relative risk of having OSAS of 5.51 and of 
2.73, respectively.
Table 3. Multivariate analysis by logistic regression of associ-
ated comorbidities independently of OSA
Parameters p RR CI 95% 
inferior
Superior
Overweight 0.007 5.51 1.6 19.02
Arterial hyper-
tension
0.014 2.73 1.2 6.1
Patients with OSAS were more often on medical treatment for dyslipid-
emia (92%) when compared to controls (84%, p ≤ 0.001).
According to AHI, patients were distributed by severity 
(Table 4). 
Table 4. OSAS case distribution according to severity
Apnea/Hypopnea Index Cases (%)
< 5
Mild (≥ 5 and < 15)






AHI < 5; mild: ≥ 5 and < 15; moderate: ≥ 15 and < 30; severe: ≥ 30. 
The data is presented by absolute and standard deviation frequency. 
n = 60.      



























Table 5 shows the prevalence of dyslipidemia, distributed by 
the severity of OSAS, estimated by AHI. No statistically signifi-
cant differences were observed in the presence of dyslipidemia 
among the patients with different levels of severity using the 
chi-squared test. The prevalence of dyslipidemia was lower in 
patients with moderate OSAS (13%) compared to patients with 
AHI < 5 (20%) and mild OSAS (22%).




< 5 Mild Moderate Severe p
Dyslipidemia 20% 22% 13% 25% 0.322
Absence of OSA: < 5; OSA presence: > 5: mild: ≥ 5 and < 15; moderate: ≥ 
15 and < 30; severe: ≥ 30. The data is presented by absolute frequency 
in percentage. n = 60. The chi-squared test was used.          
Discussion
As was reported in other studies, we found that overweight, 
arterial hypertension and diabetes mellitus type 2 were associ-
ated with OSAS [5, 6, 10, 17]. Overall, these values were higher 
than those described in other studies [5, 6, 10, 17]. Such a fact 
might be explained by the reduced size of the sample and pos-
sible bias in the selection of patients from only two health units 
used in the sample collection. 
It has been shown that overweight plays an important role 
in the development of OSAS [5, 14]. In this sample with OSAS, 
97% were overweight, a higher prevalence than previously [14]. 
The prevalence of overweight was significantly more frequent 
in patients with OSAS. It is described that 40% of patients with 
OSAS have arterial hypertension, but this value could be higher 
if we consider the fact that some patients with arterial hyper-
tension are thought to have hidden OSAS [14]. A type 2 diabetes 
mellitus prevalence of 43% was found, significantly higher in pa-
tients with OSAS. OSAS can be involved in the pathogenesis of 
glucose metabolism alteration [14].
The prevalence of dyslipidemia in OSAS patients in this 
study is higher than the values found in patients without OSAS, 
with significant statistical differences in bivariate analysis. For 
this association, studies are scarce, and evidence is limited [7, 
12]. Some studies show a relationship between dyslipidemia 
and the prevalence of OSAS [2, 4, 10–15, 18], although a clear 
association has not yet been shown [2, 4, 12, 13, 15]. 
A multivariate analysis was carried out in order to exclude 
confounding variables. A significant independent relationship 
was found between OSAS and overweight (OSAS risk 5.51 times 
higher) and between OSAS and arterial hypertension (OSAS risk 
2.73 times higher).
As for type 2 diabetes mellitus, its relation to OSAS was not 
independent from the other factors, although the prevalence of 
type 2 diabetes mellitus was higher in patients with OSAS. This 
was reversed when the confounding factors were adjusted, as 
was seen in other studies [10]. 
In the multivariate analysis, there was no significant and in-
dependent association between dyslipidemia and OSAS, which 
might reinforce the hypothesis of OSAS not being independently 
related to dyslipidemia. However, its presence in these patients 
might be better explained by an association with other present 
comorbidities (overweight, arterial hypertension and diabetes 
mellitus type 2). The state of insulin resistance is a mechanism 
that might be present in the development of the previous co-
morbidities, particularly in the origin of metabolic syndrome 
[19–22]. Some studies even suggest OSAS as being one of the 
components of metabolic syndrome [10], classifying it as syn-
drome Z [10, 14, 19, 23]. Thus, the dyslipidemia which occurs 
in a patient with OSAS can be related to the metabolic altera-
tions that lead to the development of atherosclerosis, worsen-
ing cardiovascular outcomes [21]. The fact that treatment with 
CPAP has shown a mild improvement in metabolic changes [12, 
18, 24–27] might explain the fact that these may not be directly 
associated to OSAS. Other studies state that night chronic hy-
poxemic state, present in OSAS, is independently related with 
dyslipidemia [4] in spite of limited evidence [15].
Previous studies have shown that dyslipidemia might be re-
lated to the severity of OSAS [2, 7]. In this study, this possible 
relationship was evaluated using AHI. No statistical differences 
were observed between the prevalence of dyslipidemia and the 
different degrees of severity of OSAS (< 5, light, moderate and 
severe). The prevalence of dyslipidemia in OSAS patients with 
AHI < 5 was 20%, in mild OSAS – 22%, and in severe OSAS – 25%, 
meaning that the prevalence might increase with the severity of 
OSAS. However, in the case of moderate OSAS, the prevalence 
of dyslipidemia was only 13%. These results were also found in 
other studies [2]. This might be explained by the reduced sam-
ple size, by the high levels of omissions of registration of the 
AHI parameter and by the fact that there was a small number of 
patients with moderate OSAS. As mentioned before, as well as 
in other studies, the confounding factors (overweight, arterial 
hypertension and diabetes mellitus) may represent a determin-
ing role in the lipid profile of patients and in the different stages 
of OSAS severity [2, 7].
As for limitations of this study, one must bear in mind the 
reduced size of the sample, even though it was calculated to 
be representative of the population. We studied a mostly male 
sample, which is in accordance with previous studies [2, 5, 6]. 
The average age was 63.7 ± 10.0 years, an older age than most 
other studies described [2, 5, 6]. This fact might be explained 
by underdiagnosed OSAS in Portugal or be the consequence of 
a late diagnosis [5]. 
Another limitation could be the fact that the information re-
corded in the electronic clinical processes might not be correct or 
was missing, namely for the Apnea/Hypopnea Index (IAH). Future 
studies will be needed to better explain this relationship in larger 
samples and while excluding possible confounding factors. 
Conclusions
In our sample, patients with OSAS had a higher prevalence 
of dyslipidemia which was not independent from other cardio-
vascular risk factors. Dyslipidemia might be better explained in 
OSAS patients in a context of associated overweight and cardio-
vascular risk. Dyslipidemia and OSAS severity were not statisti-
cally associated.
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